Your session is about to expire
What is Myzilra
LevonorgestrelThe Generic name of this drug
Treatment SummaryEthinylestradiol is a synthetic form of estrogen that was created in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was designed to have a greater ability to be absorbed when taken orally. Ethinylestradiol was approved by the FDA in 1943 and is used in many contraceptive pills.
Triphasil-21is the brand name
Myzilra Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Triphasil-21
Levonorgestrel
1984
243
Approved as Treatment by the FDA
Levonorgestrel, also known as Triphasil-21, is approved by the FDA for 6 uses including Postmenopausal Osteoporosis and Menopause .Postmenopausal Osteoporosis
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
Menopause
Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol
Has had at least 1 child
moderate Menopausal Vasomotor Symptoms
Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol
Emergency Contraception
Hot flashes
Used to treat Menopause in combination with Estradiol
Effectiveness
How Myzilra Affects PatientsEthinylestradiol is a type of artificial estrogen that stops ovulation and lowers the risk of endometrial growth by decreasing two hormones (LH and gonadotrophic). This drug should be taken once daily and is considered safe, although there is a risk of thrombotic events.
How Myzilra works in the bodyEthinylestradiol is a synthetic version of the female hormone estrogen. Taking it can reduce bone density and suppress ovulation. It does this by blocking the hormones responsible for ovulation, thickening the cervical mucus to prevent sperm from traveling, and preventing changes in the endometrium. It also lowers luteinizing hormone and increases sex hormone binding globulin.
When to interrupt dosage
The suggested measure of Myzilra is contingent upon the diagnosed condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The amount of dosage relies on the method of delivery as featured in the table beneath.Condition
Dosage
Administration
Endometriosis
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Hot flashes
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
moderate Menopausal Vasomotor Symptoms
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Hypermenorrhea
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Postmenopausal Osteoporosis
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Endometrial Hyperplasia
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Emergency Contraception
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Has had at least 1 child
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Menopause
, 0.75 mg, 1.5 mg, 52.0 mg, 1.39 mg, 0.15 mg, 0.1 mg, 36.0 mg, 0.25 mg, 0.125 mg, 0.075 mg, 13.5 mg, 0.09 mg, 1.5 mg/mg, 19.5 mg, 0.0015 mg/hour, 0.03 mg, 0.05 mg, 0.45 mg, 2.6 mg, 0.3 mg
Oral, Kit - Oral, , Kit, Tablet, Tablet - Oral, Intrauterine, Intrauterine device, Intrauterine device - Intrauterine, Transdermal, Patch - Transdermal, Patch, Insert, extended release, Insert, extended release - Intrauterine, Subcutaneous, Implant, Implant - Subcutaneous, Tablet, film coated, Tablet, film coated - Oral
Warnings
Myzilra ContraindicationsCondition
Risk Level
Notes
Septic Abortion
Do Not Combine
undiagnosed abnormal genital bleeding
Do Not Combine
infected abortions
Do Not Combine
HCG elevated
Do Not Combine
Pelvic Infection
Do Not Combine
Vaginitis
Do Not Combine
Acute Coryza
Do Not Combine
presence or history of breast cancer
Do Not Combine
Uterine Cervicitis
Do Not Combine
Communicable Diseases
Do Not Combine
gonococcal cervical infection
Do Not Combine
Breast Cancer
Do Not Combine
Intrauterine Devices
Do Not Combine
Neoplasms, Hepatic
Do Not Combine
congenital or aquired uterine abnormality
Do Not Combine
Chlamydia Infections
Do Not Combine
Hypersensitivity
Do Not Combine
Emergency Contraception
Do Not Combine
Bacterial Endocarditis
Do Not Combine
lower genital tract infection
Do Not Combine
suspected pregnancy
Do Not Combine
Uterine Cervicitis
Do Not Combine
uterine neoplasia
Do Not Combine
Pelvic Inflammatory Disease
Do Not Combine
history of progestogen-sensitive breast cancer
Do Not Combine
Cervical Neoplasia
Do Not Combine
Fibroid Tumor
Do Not Combine
Postpartum Endometritis
Do Not Combine
chlamydial cervical infection
Do Not Combine
PAP Test Abnormalities
Do Not Combine
acute liver disease
Do Not Combine
Uterine anomaly distorting uterine cavity
Do Not Combine
Breast Cancer
Do Not Combine
Cervical Dysplasia
Do Not Combine
Thromboembolism
Do Not Combine
Bacterial Vaginosis
Do Not Combine
history of pelvic inflammatory disease
Do Not Combine
Breast
Do Not Combine
Vaginal Bleeding
Do Not Combine
Bacterial Vaginosis
Do Not Combine
Pelvic Inflammatory Disease
Do Not Combine
gonococcal cervical infection
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Levonorgestrel may interact with Pulse Frequency
Common Myzilra Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Levonorgestrel.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Levonorgestrel.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Levonorgestrel.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Levonorgestrel.
Crizotinib
Major
The metabolism of Crizotinib can be decreased when combined with Levonorgestrel.
Myzilra Toxicity & Overdose RiskWomen who overdose on this drug may experience menstrual bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. Treatment should focus on supportive care and monitoring for changes in potassium and sodium levels, as well as signs of acidosis.
Myzilra Novel Uses: Which Conditions Have a Clinical Trial Featuring Myzilra?
38 active clinical trials are presently assessing the potential of Myzilra to provide Folate supplementation therapy, alleviate Premenstrual Dysphoric Disorder symptoms and manage Menopause.Condition
Clinical Trials
Trial Phases
Menopause
0 Actively Recruiting
Endometriosis
30 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1
Hot flashes
22 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1
Has had at least 1 child
0 Actively Recruiting
Emergency Contraception
1 Actively Recruiting
Phase 4
Endometrial Hyperplasia
9 Actively Recruiting
Phase 2, Not Applicable
Hypermenorrhea
0 Actively Recruiting
Postmenopausal Osteoporosis
3 Actively Recruiting
Not Applicable, Phase 4
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Myzilra Reviews: What are patients saying about Myzilra?
5Patient Review
11/14/2014 I've been using this birth control for three years now and have had great results. No side effects that I've noticed, and it's been very effective at preventing pregnancy.
4.7Patient Review
7/5/20124.3Patient Review
1/19/2016 I've been using this birth control for a few years now and have had mostly positive experiences. My periods are regular and relatively short, which is great. The only downside is that I've gained about 10 pounds since starting the medication - even though my diet hasn't changed.
4Patient Review
9/15/2017 I took this pill for approximately three years. However, in the last year I experienced increasingly negative side effects, such as debilitating mood swings and a total loss of sex drive. Additionally, hot flashes became more frequent and intense. Consequently, I stopped taking the pill last month and have already noticed an improvement.
3.7Patient Review
2/7/2013 I experienced some breast pain, sensitivity, and migraines when I first started taking myzilra. However, these symptoms have all cleared up after a few weeks. I'm not sure about the pill's effect on my mood just yet, but so far so good. The cramps are still there but they're much less severe than before.
3.7Patient Review
6/12/2014 I had high hopes for this treatment, but unfortunately it made my cramps and acne worse.
3.3Patient Review
12/11/2013 I would not recommend this birth control to anyone. It's made my acne worse, and the first pills of each new pack make me so sick that I vomit and have sore breasts.
3.3Patient Review
2/5/2015 I've been taking birth control pills for years with no issue, but the past year has been terrible since they switched my pill to a generic brand. I experienced cramps, weight gain, headaches and mood swings. If you can avoid this pill, do so. It's really impacted my life negatively.
3Patient Review
12/27/2017 I experienced some benefits with this treatment, but they were not worth the host of problems that came with it. The generic version caused me to gain 20 pounds, suffer from headaches and acne, and even experience hallucinations. I'm glad I stopped taking it.
1Patient Review
12/6/2012 Myzilra made me so tired and sapped all of my energy. In addition to that, I started getting headaches and then seasonal allergies (which is strange because I never get them). I think this lowered my immune system because now I feel sick constantly.
Patient Q&A Section about myzilra
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are birth control side effects?
"The side effects that are most common with birth control pills are spotting or bleeding between periods, sore breasts, nausea, or headaches. However, these side effects usually go away after 2 or 3 months, and not everyone who takes the pill experiences them. Birth control shouldn't make you feel sick or uncomfortable."
Answered by AI
Can birth control increase blood pressure?
"Birth control containing estrogen can increase blood pressure. This is a problem for women who have high blood pressure because they have an increased risk of stroke and heart attack compared with women who do not have high blood pressure."
Answered by AI
Why am I still bleeding on birth control pills?
"If you experience breakthrough bleeding while using birth control, it is most likely to occur in the first three months of use, or when switching to a new type of birth control."
Answered by AI
Can I get pregnant if I miss a pill?
"If you have missed a pill or started a new pack one day late, you are still protected against pregnancy. You should take the last pill you missed now, even if that means taking two pills in one day."
Answered by AI